. (1976). Annals ofthe Rheumatic Diseases, 35, 40-45. Serum immunoreactive gastrin: specificity for rheumatoid arthritis, bimodality of distribution, and failure of effect of anti-inflammatory drugs. A significant rise in immunoreactive gastrin in a proportion of patients with rheumatoid arthritis is confirmed. Such a rise does not seem to occur in other inflammatory or tissue destructive diseases. The patients with raised immunoreactive gastrin appear to form a separate population but the factors determining this separation remain obscure. Anti-inflammatory drugs, at least during short-term administration have no influence on immunoreactive gastrin concentrations.
We recently reported that in a proportion of patients with 'definite' or 'classical' rheumatoid arthritis the serum immunoreactive gastrin (IRG) concentration was markedly raised; often in fact to a level which is normally associated with the Zollinger-Ellison syndrome (Rooney and others, 1973b) . In further work investigating the mechanism of this rise we showed that serum immunoreactive gastrin levels rose during the induction of adjuvant arthritis in rats (Rooney and others, 1973a) , placing the effect firmly within the inflammatory process. More recently we showed a remarkably close correlation between gastric acid output and serum immunoreactive gastrin levels during pregnancy and the puerperium, documenting both a rise in IRG levels in late pregnancy and early puerperium and marked hypergastrinaemia of the immediate neonatal p2riod when severe gastric hyp-racidity is common (Rooney and others, 1975b) .
In studies with the liquorice derivative, carbenoxolone sodium, which is unique in possessing both anti-inflammatory and ulcer-healing properties, we were able to show a significant rise in immunoreactive secretin concentrations which paralleled the expected changes in plasma electrolytes and acid-base concentrations but were unable to show any consistent change in serum IRG concentrations (Rooney and others, 1974) .
In the present paper we report further studies of IRG concentration in an extended group of patients with rheumatoid arthritis in which there is evidence of a bimodal distribution of IRG. We have also compared the IRG concentrations obtained in normal subjects and in patients with rheumatoid arthritis with IRG levels measured in other inflammatory and tissue-destructive diseases, the results of which tend to focus our attention upon the 'disease' rheumatoid arthritis. In addition we report the results of serum IRG concentrations measured before and after the administration of standard anti-inflammatory drugs given alone to patients with rheumatoid arthritis.
Patients and methods

RHEUMATOID ARTHRITIS
152 patients with 'definite' or 'classical' rheumatoid arthritis according to the criteria of the American Rheumatism Association (Ropes and others, 1959) these patients and in none was serum lipoprotein abnormalities likely to be aetiological in the infarction (Rooney, Ballantyne, and Buchanan, 1975a) . When blood was drawn for serum IRG concentrations these patients had all been pain free for at least 72 hours.
CONTROLS
The controls used for this study were 102 patients attending an accident and emergency department with minor trauma who gave no clinical history of major systemic disease, particular attention being paid to disease of the locomotor, gastrointestinal, and genitourinary systems. Their mean age was 47-3 years (range 21-74 years).
DRUG STUDIES
The effect of 14 days' treatment with a single anti-inflammatory drug on the serum IRG concentration was studied in small groups of patients with 'classical' rheumatoid arthritis. The drugs used were soluble aspirin 3 g daily, indomethacin 200 mg daily, phenylbutazone 300 mg daily, tetracosactrin 0-5 mg daily, and ascorbic acid 500 mg daily. Clinical assessment on day 0 and day 7 included articular index, pain index, and patient assessment numerically graded. Blood was withdrawn at the same time for measurement of IRG concentration and erythrocyte sedimentation rate.
IMMUNOREACTIVE GASTRIN
In all instances serum for IRG estimation was withdrawn after a 14-hour overnight fast. IRG was assayed by a sensitive and specific radioimmunoassay. This depends upon specific antibody raised in rabbits to synthetic human gastrin I. Radiolabelling of the hormone is accomplished by a modification of the chloramine T method (Hunter and Greenwood, 1962) . Separation of free from antibody-bound hormone is achieved using dextrancoated charcoal (Buchanan and McCarroll, 1971) . The sensitivity of this method is greatest below 600 pg/ml and the lower limit of reliable detection is of the order of 10 pg/ml. The antibody used detects the heptadecapeptide as well as 'big' and 'big big' gastrin (Yalow and Berson, 1972) and there is minimal cross reactivity with cholecystokinin pancreozymin.
Results
The results are shown in Table II and the Figure. If we take the IRG in the patients with rheumatoid arthritis as belonging to a single population the mean level would be 312 pg/ml + 463-0 pg/ml (SD). This is significantly greater than the mean level in the control group of normal subjects (56 ± 133-6 pg/ml SD) (t = 5-46; 0-005 <P <0001 (Spiegel, 1972) . 15-6 ± 3.2 12-8 ± 2-4 11-4 ± 3-2 11-2 ± 3-7 Indomethacin 200 mg/d 152 + 27 143 ± 22 17-4 ± 3-4 16-4 ± 2-8 8-2 ± 3-2 11.2 ± 2-4 Phenylbutazone 300 mg/d 127 ± 9 138 + 11 5-3 ± 4-0 7-2 ± 3 0 15-1 ± 3-9 16-4 ± 5-2 Tetracosactrin 2-5 mg/d 111 + 9
118 + 7 17-3 ± 3-2 12-1 ± 3-2 15-2 ± 1-8 12-1 + 3-4 Ascorbicacid 600mg/d 172±33 162+24
12-1 ± 1±1 12-2+ 1-7 15-8± 3-2 14-9±2-4
same results plotted on a logarithmic scale and in this way the distribution is normalized, giving a coefficient of skewness of 3-15 and a coefficient of kurtosis of 2 54. The Figure also shows the IRG results obtained in the rheumatoid patients. Most of these results parallel the distribution of the controls but the curve can be seen to be bimodal with a second peak of incidence between 103 and 103-5 pg/ml of immunoreactive gastrin. Arbitrary division of both the control population and the patients with rheumatoid arthritis at the level of 1025 pg/ml IRG shows that of 102 control subjects only two had levels greater than this value whereas of 152 patients with rheumatoid arthritis 33 lay above this level. A x2 test of these figures suggests that this difference is highly significant (x2= 20-0; P < 0-001). Using this same arbitrary division an F test suggests that the two groups of patients with rheumatoid arthritis are samples of different populations (F = 17-15; P < 0 002).
There was no significant relationship between serum IRG concentration and any of the clinical or laboratory tests undertaken in this study. In particular there was no relationship between serum IRG and articular index, erythrocyte sedimentation rate, rheumatoid factor titre, or serum immunoglobulin concentration.
The results of the serum IRG concentration before and after standard dose regimens of aspirin, indomethacin, phenylbutazone, and prednisolone are shown in Table III . It can be seen that no predictable change occurred either in the pre-and postserum IRG concentrations or in the changes in IRG compared with the change in either clinical or laboratory indices. That the drugs were being absorbed is indicated by the clinical effect shown by the changes in assessment indices.
Discussion
The study of raised serum IRG concentrations in rheumatoid arthritis is becoming more interesting as early possible explanations of the phenomenon are being excluded.
In rheumatoid arthritis anti-inflammatory drugs, which are being used constantly and universally in this disease, seemed to be a likely cause of the immunoreactive hypergastrinaemia. Two observations refute this. In the first place individual studies with these drugs reported here showed that these drugs had no effect whatsoever on the serum IRG concentrations, and serum IRG levels are not raised in inflammatory joint disease of nonrheumatoid origin in patients receiving roughly comparable drug therapy. In the second place we have reported elsewhere (Rooney and others, 1973a ) that IRG levels rise when adjuvant arthritis is induced in rats, an experiment in which no anti-inflammatory drug was used. It seems unlikely therefore that this effect is drug induced.
A further possibility was that the high IRG levels in rheumatoid arthritis represented simply another nonspecific acute phase reactant. Again certain observations are contrary to this interpretation. No rise of the serum IRG concentration could be shown in this study in nonarthritic inflammatory or tissuedestructive diseases such as active pulmonary tuberculosis or myocardial infarction. Also the rise in IRG in rheumatoid arthritis is not related to other clinical and laboratory indices of the severity of the inflammatory process at the time of study. Finally, and most remarkably, raised serum IRG levels have not been observed yet in related inflammatory joint diseases such as psoriatic arthritis, systemic lupus erythematosus, or ankylosing spondylitis, an important finding when one considers how few parameters of disease are abnormal, exclusively in rheumatoid arthritis. Although the numbers studied in this present sample are too few to conclude that serum IRG is never raised in these other diseases, they are sufficient to focus our attention on the relationships between raised serum IRG and rheumatoid or adjuvant arthritis.
There remains the early suggestion that the profusion of immunological deviations that occur in rheumatoid arthritis were in some way interfering with the radioimmunoassay. That the most obvious contender, namely IgM rheumatoid factor was not the entity responsible was established in our first result (Rooney and others, 1973b) in which raised serum IRG occurred in seronegative patients. It is still possible that IgG rheumatoid factor (Torrigiani and Roitt, 1967) or IgG anti-IgG complexes are responsible, but is less likely when one considers that serum IRG concentrations are not raised in psoriatic arthritis, in which these are known to occur (Tapanes, Rawson, and Hollander, 1972) and in systemic lupus erythematosus, a disease in which a diverse range of antigen-antibody complexes (Kunkel and others, 1961) and of autoantibodies (Hart, 1970) occurs. It is also noteworthy in view of the recent report of interference with radioimmunoassay results of TSH by immunoglobulins (Chapman, Hutton, and Hatter, 1974) that there was no relationship in the present study between serum IRG concentrations and immunoglobulin levels either in the patients with rheumatoid arthritis or in those with systemic lupus erythematosus.
We are therefore left with the observation that raised IRG concentrations in rheumatoid arthritis are unlikely to be due to drugs, although it is fair to point out that studies over a period of 14 days do not exclude a pharmacological effect of compounds which have been used for many years. Nor is it likely that the raised IRG concentrations relate to interfering nonspecific immunoglobulins and they probably do not represent a nonspecific acute phase reactant. A difficult and central problem is posed by the coexistence of markedly raised serum IRG together with normal gastric acid output and normal gastric mucosal histology (Rooney and others, 1974) . There is no evidence of end-organ failure, so either the hormone measured by radioimmunoassay is not biologically active or its action is blocked in some way.
The recent observations on the heterogeneity of circulating gastrin (Walsh, Debas, and Grossman, 1973) have suggested that the larger molecules in the circulation have a lesser biological activity than those smaller entities such as 'G-17-I' and 'G-17-IL' or 'G-34-I' and 'G-34-II'. Until full gel filtration studies and bioassay studies are completed the possibility remains that the high levels of IRG observed in rheumatoid arthritis are due to large biologically inert forms of the hormone.
Biological blockade is also possible and the recent observations that prostaglandins can inhibit the effect of gastrin (Karim and others 1973) and the implication of compounds of this type in the inflammatory reaction (Greaves, Sondergaard, and McDonald Gibson, 1971) suggest one possible mechanism of this type.
Perhaps the most exciting observation in the present study is that within the population of rheumatoids, which we currently view as 'homogeneous' by the criteria of seropositivity joint erosions, and a chronic peripheral, inflammatory polyarthritis, by at least one criterion there appears to exist a bimodal distribution. It is now essential to determine if these subgroups exhibit any difference, clinically, pharmacologically, or immunologically; and the result encourages us to pursue our studies to look for other 'handles' by which we can more definitively subclassify this enigmatic condition which may represent, like 'Bright's kidney', a limited tissue response to widely different initiating mechanisms.
